NCT02925403View on ClinicalTrials.gov

A Study to Assess the Safety and Immunogenicity of the Malaria Vaccine, R21, With Matrix-M1 Adjuvant

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

13

Participants

Timeline

Start Date

August 26, 2016

Primary Completion Date

February 15, 2017

Study Completion Date

February 15, 2017

Conditions
Malaria
Interventions
BIOLOGICAL

R21/Matrix-M1

OTHER

Saline

Trial Locations (1)

Unknown

Centre National de Recherche et de Formatation sur le Paludisme (CNRFP)/Unite de Recherche Clinique de Banfora (URC-B), Ouagadougou

All Listed Sponsors
lead

University of Oxford

OTHER

NCT02925403 - A Study to Assess the Safety and Immunogenicity of the Malaria Vaccine, R21, With Matrix-M1 Adjuvant | Biotech Hunter | Biotech Hunter